Associations between antenatal prednisone exposure and long-term cortisol and cortisone concentrations in children born to women with rheumatoid arthritis: results from a nationwide prospective cohort study by Ince-Askan, H. (Hilal) et al.
  1Ince-Askan H, et al. RMD Open 2019;5:e000852. doi:10.1136/rmdopen-2018-000852
Original article
Associations between antenatal 
prednisone exposure and long-term 
cortisol and cortisone concentrations in 
children born to women with 
rheumatoid arthritis: results from a 
nationwide prospective cohort study
Hilal Ince-Askan,  1 Erica L T van den Akker,2 Yolanda B de Rijke,3 
Elisabeth F C van Rossum,4 Johanna M W Hazes,1 Radboud J E M Dolhain1
To cite: ince-askan H, 
van den akker elt, de rijke YB, 
et al. associations between 
antenatal prednisone exposure 
and long-term cortisol and 
cortisone concentrations in 
children born to women with 
rheumatoid arthritis: results 
from a nationwide prospective 
cohort study. RMD Open 
2019;5:e000852. doi:10.1136/
rmdopen-2018-000852
 ► Prepublication history and 
additional material for this 
paper are available online. to 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ rmdopen- 2018- 
000852).
received 7 november 2018
revised 3 January 2019
accepted 8 January 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Hilal ince-askan;  
 h. ince- askan@ erasmusmc. nl
Rheumatoid arthritis
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY-nc. no 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
AbstrAct
Objectives to identify whether children with antenatal 
prednisone exposure have chronically elevated cortisol 
and cortisone concentrations, an altered body composition 
or higher blood pressure. in addition, to identify whether 
maternal rheumatoid arthritis disease (ra) activity is 
associated with these alterations.
Methods in this prospective study, 56 children (mean 
age=10.0 years) with and 61 children (mean age=9.6 years) 
without antenatal prednisone exposure, born to women with 
ra, were included. Hair cortisol and cortisone were analysed 
using liquid chromatography–tandem mass spectrometry. 
linear regression models were built to analyse differences 
between the two groups, corrected for relevant covariates. 
Hair cortisol concentrations were also compared between 
the study population and an age-matched healthy reference 
group(n=150 children, mean age=9.8 years).
Results Hair cortisol and cortisone concentrations were 
similar in children with and without antenatal prednisone 
exposure (median cortisol 1.14 pg/mg (iQr 0.67–1.75) and 
1.15 pg/mg (iQr 0.65–2.21) and median cortisone 6.76 
pg/mg (iQr 5.42–8.86) and 7.40 pg/mg (iQr 5.39–10.73), 
respectively). antenatal prednisone exposure and maternal 
ra disease activity were also not associated with body 
composition or blood pressure. Hair cortisol concentrations 
were not different in children born to mothers with ra 
compared with children from the reference group.
Conclusion this, in its kind, large and unique long-term 
prospective study demonstrates that low-dose antenatal 
prednisone exposure and maternal ra disease activity are 
not associated with negative consequences in prepubertal 
childhood. the findings of this study are reassuring and 
support the assumption that low-dose maternal prednisone 
use during pregnancy is safe for the offspring, at least until 
the age of approximately 10 years.
Ideally during pregnancy, women would not 
use any medication; however, sometimes it 
is inevitable, like the use of corticosteroids in 
autoimmune disorders. In animal studies, it has 
been shown that an excess of maternal gluco-
corticoids during pregnancy, for example, 
administration of synthetic glucocorticoids, 
is associated with altered hypothalamic-pitu-
itary-adrenal (HPA) axis activity with higher 
plasma cortisol levels of the offspring, higher 
blood pressure, hyperglycaemia and visceral 
obesity in later life.1–7
There are also several human studies 
demonstrating that adverse circumstances 
during pregnancy, that are related with 
cortisol concentrations in the mother (eg, 
maternal stress,8 maternal depression9–11 
Key messages
What is already known about this subject?
 ► research on the long-term consequences of antena-
tal prednisone exposure has been limited.
What does this study add?
 ► in this unique nationwide study, the majority of the 
participants were followed prospectively during and 
after pregnancy.
 ► Scalp hair measurement of cortisol and cortisone is 
considered the most optimal method for long-term 
concentrations.
 ► low-dose antenatal prednisone exposure and 
maternal disease activity are not associated with 
long-term negative consequences in prepubertal 
childhood.
How might this impact on clinical practice?
 ► the findings of this study are reassuring for wom-
en with an autoimmune disease who use low-dose 
prednisone during pregnancy.
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and maternal anxiety during pregnancy12–14), result in 
elevated cortisol concentrations and an altered cortisol 
response in the offspring. Chronically elevated cortisol 
levels are associated with an increased risk of abdominal 
obesity, hypertension, non-insulin dependent diabetes 
mellitus and cardiovascular disease.15–20
Maternal cortisol rises throughout pregnancy, but 
normally only 10%–20% reaches the fetus due to the 
oxidation of cortisol to cortisone by 11beta-hydroxyste-
riod dehydrogenase type II (11βHSD2) enzyme in the 
placenta.21–23 Cortisone can be reverse metabolised into 
cortisol.24 The 11βHSD2 enzyme also converts the active 
prednisolone into its inactive metabolite prednisone.25 
Despite the presence of this enzyme, children born to 
mothers who use prednisone during pregnancy could be 
exposed to higher concentrations of corticosteroids in 
utero in at least three different ways.
First, since the placenta is not fully developed before 
12 weeks of gestation, in that period passive diffusion 
of prednisolone to the fetus takes place.26 Second, the 
capacity of the 11βHSD2 enzyme may be exceeded by the 
external administration of corticosteroids,26 27 resulting in 
increased placental availability of prednisolone. Finally, 
the activity of 11βHSD2 is downregulated by the proin-
flammatory cytokines tumour necrosis factor (TNF), 
interleukin (IL)-1 and IL-6, which are elevated in auto-
immune disorders like rheumatoid arthritis (RA),26 28 
resulting in decreased inactivation and increased avail-
ability of prednisolone.
Exposure to higher corticosteroid concentrations 
in utero may influence the development of the fetal 
HPA-axis, with reduced negative feedback due to reduc-
tion in hippocampal glucocorticoid receptor expression.2 
As a result, this may lead to an overactive HPA-axis and 
elevated circulating glucocorticoids in the offspring.2
De Steenwinkel et al26 reported that children born to 
mothers with RA who used prednisone during pregnancy 
had higher salivary cortisol levels at the age of approxi-
mately 7 years, independent of RA disease activity of the 
mother during pregnancy.26 However, there was no asso-
ciation with physical signs of higher cortisol levels. The 
main limitation of that study is that the analysis of cortisol 
was from a single day saliva sample collection, which is a 
useful method to study acute HPA-axis reactivity, but is 
not a good reflection of long-term cortisol levels.29 30
Since then, a new method has become available to 
measure both long-term cortisol and cortisone concentra-
tions in scalp hair.31 Several studies have shown that this is 
a reliable, non-invasive method to measure endogenous 
cortisol and cortisone, in adults32–35 and in children.30 36 37 
Hair cortisol is a reflects long-term cortisol exposure.30 
It has been shown that obese children have higher hair 
cortisol concentrations compared with non-obese chil-
dren.24 30 Furthermore, in a large population-based 
cohort, hair cortisol concentrations were already asso-
ciated with body mass index (BMI) and adverse body 
fat distribution in children at young age (mean age of 
6 years).38 Also, children’s hair cortisol levels have been 
shown to be associated with stress at school entry.37
Hair cortisol and cortisone analysis could provide more 
information about the long-term consequences of ante-
natal prednisone exposure.
In the current study, we investigated whether children 
with antenatal prednisone exposure have signs of altered 
HPA-axis activity, reflected by chronically elevated hair 
cortisol and cortisone concentrations, an altered body 
composition (risk factors for future cardiovascular and 
metabolic disease) or higher blood pressure compared 
with children without antenatal prednisone exposure. 
In addition, since proinflammatory cytokines may cause 
downregulation of 11bHSD2 followed by increased 
transfer of prednisolone to the fetus, we analysed the 
associations between maternal RA disease activity during 
pregnancy and the earlier mentioned outcome measures 
in childhood.
MeTHOds
study population
In a previous study26 that showed that antenatal pred-
nisone exposure is associated with elevated cortisol 
concentrations in saliva at the age of approximately 7 
years, 42 children with and 63 children without pred-
nisone exposure were included. Hair cortisol concentra-
tions correlate with long-term salivary cortisol production 
measured over a 1-month period.32 Therefore, in order 
to acquire enough power in this prospective cohort study, 
we aimed to include comparable numbers of participants. 
In this study, a total of 56 children with (prednisone dose 
≥5 mg/day, during at least 2 trimesters of pregnancy) 
and 61 children without antenatal prednisone exposure 
born to women with RA, aged 515 years, were included 
between 2014 and 2018.
First, children born to women who participated in the 
Pregnancy induced Amelioration of Rheumatoid Arthritis 
(PARA) study were included, a nationwide prospective 
cohort study on RA and pregnancy and onwards from 
the Netherlands.39 The PARA study has been described 
in detail elsewhere.39 In the PARA study, patients with RA 
who met the 1987 revised American College of Rheuma-
tology criteria40 with a wish to conceive or already preg-
nant, were enrolled between 2002 and 2008 (last visit in 
2010).
Second, siblings of the children born to PARA-partic-
ipants were included (if their mother was already diag-
nosed with RA before pregnancy). Finally, after the 
inclusion was not sufficient, children born to women with 
RA who visited the outpatient clinic of the department 
of Rheumatology in the Erasmus MC Rotterdam, the 
Netherlands, were included to accomplish the intended 
number of inclusions. At this outpatient clinic, RA disease 
activity and medication use during pregnancy are prop-
erly recorded.
In total, 97 children born the PARA study participants, 
14 siblings and 6 children born to women who visited the 
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outpatient clinic were included. Exclusion criteria were: 
congenital abnormalities, chronic illness of the child, 
non-Caucasian ethnicity, scalp hair shorter than 2 cm.
Reference population
As a reference population, 252 healthy children born to 
women from the general population were used. These 
children had been recruited, as described in more detail 
elsewhere.41 Briefly, children were eligible for inclusion if 
they were between the age of 4 and 18 years, did not use 
glucocorticoids 3 months prior to or during the study and 
did not suffer a chronic disease. Healthy controls were 
recruited from primary and secondary schools in the 
Netherlands and among siblings of children attending 
the paediatric outpatient clinic.41 For comparison with 
the current study, only data on Caucasian children 
between the age of 5 and 15 years was used, resulting in 
150 participants in the reference group.
data collection
Data collection during pregnancy
In the PARA-study, participants were visited at their 
home address before pregnancy (if possible), three times 
during pregnancy and three times after the birth of the 
child (at 6, 12 and 26 weeks). At all time-points, data 
on mother and child were collected. RA disease activity 
was measured using the Disease Activity Score based on 
3 variables; swelling and tenderness by palpation in 28 
joints and a C reactive protein (DAS28-CRP(3)). For 
participants whose mother did not participate in the 
PARA study, information on their disease activity and 
medication use during pregnancy, pregnancy course and 
pregnancy outcome (from 1 year before delivery until 1 
year after delivery) was obtained from their rheumatolo-
gist and gynaecologist.
Hair collection
Participants were visited at their home address once 
during the study period. During this visit, a lock of 3 cm 
with approximately 100 hairs was cut from the posterior 
vertex of the child’s scalp, as close to the scalp as possible. 
There is a wide consensus that proximal parts of the hair 
reliably reflect chronic cortisol concentrations.42 Exoge-
nous environmental factors, such as frequent hair washing 
and cosmetic treatments could decrease cortisol levels in 
the more distal (older) segments of the hair.31 42–44 Addi-
tionally, sampling of hair that is taken from the posterior 
vertex is the most optimal, because the intraindividual 
variation is smallest at that site.31 34 Hair growth patterns 
vary across different regions of the scalp and the poste-
rior vertex region shows the most uniform growth rates.45 
Because hair grows approximately 1 cm per month, a hair 
sample of 1 cm is thought to reflect the mean exposure of 
cortisol in 1 month.30 46
The hair samples were taped to a piece of paper, and 
the proximal side was marked. The hair samples were 
stored at room temperature in an envelope until analysis.
Parents were also asked to fill out a questionnaire on, 
for example, frequency of washing the hair, hair colour, 
cosmetic hair treatments and medication/illness of their 
children.
anthropometry
During the visit, blood pressure, growth and body compo-
sition were also measured (height, weight, hip and waist 
circumference and skin folds using Holtain calliper). 
All measurements, except for weight, were performed 
three times. Blood pressure was measured three times in 
rest with an automatic device (Omron M6 AC; Omron 
Healthcare, Hoofddorp, the Netherlands), using a cuff 
appropriate to the size of the child’s upper arm. The 
mean of the three measurements were used in the anal-
ysis. Fat percentage was calculated using the skin folds 
(biceps, triceps, subscapular and suprailiacal) with the 
Durnin and Womersley formula.47
BMI was calculated using the formula weight (kg)/
height2(m2). Systolic and diastolic blood pressure/
height ratios were calculated, since those ratios have 
been shown to correlate with the corresponding blood 
pressure percentiles in both male and female children.48 
All other child-related values were transformed into SD 
scores (SDS) for age and gender according to the 2010 
Dutch reference values,49 using the Growth Analyser(ver-
sion 4.0; Growth analyser BV, Rotterdam, the Nether-
lands, http://www. growthanalyser. org). Birth weight was 
expressed as birth weight SDS, corrected for gestational 
age and gender.50
Data collection reference population
Hair samples and data on anthropometrics were collected 
during school visitation. Demographic information, data 
on general health, the use of medication and hair care 
were collected through questionnaires.41 Hair collection 
was performed with a similar method as in the current 
study.
Cortisol and cortisone analysis in hair
The hair samples were processed and analysed, by liquid 
chromatography–tandem mass spectrometry as described 
previously,44 at the department of Clinical Chemistry, 
Erasmus University Medical Center, Rotterdam, The 
Netherlands.
statistical analysis
For all subjects, descriptive statistics were calculated as 
numbers, percentages, means, medians, SDSs and IQRs. 
For comparing baseline characteristics, Student’s t tests 
were used for normally distributed continuous variables, 
Wilcoxon rank-sum tests for not normally distributed 
continuous variables and χ² and Fisher’s exact tests for 
categorical variables. Cortisol and cortisone were loga-
rithmically (log10) transformed to achieve a normal 
distribution. Linear regression models were built to 
analyse associations between cortisol and cortisone, 
and antenatal prednisone exposure. Factors associated 
in other studies24 51 with hair cortisol and cortisone 
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concentrations (age, sex, socioeconomic status (SES) 
based on the educational level of the mother, season of 
hair collection, hair colour, washing frequency) were 
used as independent covariables. Similarly, a regres-
sion model was built to analyse the association between 
maternal DAS28-CRP(3) during pregnancy and cortisol 
and cortisone concentrations. Furthermore, associa-
tions between cortisol, cortisone, DAS28-CRP(3) and the 
anthropometric measurements (BMI SDS, fat percentage 
SDS based on skinfolds, waist and hip circumference SDS, 
systolic and diastolic blood pressure SDS, ratio waist-hip 
circumference and ratio skinfolds trunk to skinfolds 
peripheral) were analysed using linear regression.
In addition, a linear regression analysis was performed 
to compare the cortisol concentrations children born to 
mothers with RA, with the reference population using 
stepwise backwards selection of relevant covariates (age, 
sex, weight SDS, height SDS, BMI SDS, waist circum-
ference SDS, height circumference SDS, SES, washing 
frequency and hair colour).
P≤0.05 were considered statistically significant. All 
statistical analysis were performed using STATA software 
V.15.1 for Windows.
ethics
This study is in compliance with the Helsinki Declara-
tion. The Medical Ethics Committee at the Erasmus MC 
University Medical Center Rotterdam, the Netherlands, 
approved the current study (MEC-2014–395) and the 
PARA-study (MEC-214.320/2002/117). Parents (and 
children) received oral and written information about 
the study. Informed consent was signed by both parents, 
and their children if they were aged ≥12 years.
ResulTs
Participants
In total, 252 children born to mothers with RA and both 
of their parents were invited to participate in this study 
(figure 1). From these, 58 (23.0%) did not respond 
to the invitation and could not be reached by mail or 
phone. From the 72 invited subjects who refused partici-
pation, 35 (48.6%) did not provide a reason, 16 (22.2%) 
explained that they had participated in too many studies 
and 12 (16.7%) were not interested in participation due 
to the fact that this study had to be performed in their 
children. After exclusion of five children with antenatal 
prednisone exposure <5 mg/day and/or less than during 
two trimesters, in total 117 children were included in this 
study. From these, we included 56 children who had ante-
natally been exposed to prednisone (prednisone dose ≥5 
mg/day, during at least 2 trimesters of pregnancy) and 61 
children who had not been exposed.
Participants and non-participants were compared. 
There were no statistically significant differences in 
maternal DAS28-CRP(3) in third trimester, maternal 
age at delivery, presence of autoantibodies in mother, 
SES based on educational level of the mother, sex of the 
offspring and birth weight. Gestational age was border-
line significant (p=0.05), with a median gestational age 
of 277.9 days (IQR 270.9–286.0) in participants and 275.0 
days (IQR 268.0–282.5) in non-participants.
Descriptive statistics of the study population are shown 
in table 1. Overall, the baseline characteristics were 
comparable in the prednisone and the non-prednisone 
group. Birth weight and gestational age were both signifi-
cantly lower in the group with prednisone exposure 
compared with children without prednisone exposure. 
Mean birth weight was 3167.5 g (SD=691.9) in the pred-
nisone group vs 3435.4 g (SD=584.2) in the non-predni-
sone group, p value 0.01. The median gestational age was 
273.0 days (IQR 258.0–281) in the prednisone vs 281.0 
days (IQR 274.0–287.0) in the non-prednisone group, 
p<0.001. Birth weight corrected for gestational age and 
sex was not different between the two groups. Maternal 
characteristics were also comparable in both groups, 
except for the DAS28-CRP(3), which was higher in the 
prednisone group, 3.7 (SD=1.1) vs 2.8 (SD=0.9) in the 
non-prednisone group, p<0.001. Detailed information 
on descriptive statistics of the children is provided in 
online supplementary table 1.
Associations between antenatal prednisone exposure and 
cortisol and cortisone concentrations in scalp hair
The median hair cortisol concentration was 1.14 pg/
mg (IQR 0.67–1.75) in the children with antenatal pred-
nisone exposure and 1.15 pg/mg (IQR 0.65–2.21) in the 
children without antenatal prednisone exposure. The 
median hair cortisone concentration was 6.76 pg/mg 
(IQR 5.42–8.86) in the prednisone group and 7.40 pg/
mg (IQR 5.39–10.73) in the non-prednisone group. After 
log-transformation, cortisol and cortisone were normally 
distributed. Hair cortisol and cortisone concentrations 
were not significantly different between the two groups.
In our study population, 17 children were exposed 
to prednisone with a mean dose per day ≥10.0 mg. 
Repeating the analyses in these children compared with 
the children without antenatal prednisone exposure did 
not result in significant associations between prednisone 
exposure and hair cortisol and cortisone concentrations 
(p>0.30). The median cortisol and cortisone concentra-
tions were 0.97 pg/mg (IQR 0.68–1.57) and 6.26 (IQR 
4.80–8.49) in the prednisone group (≥10.0 mg daily) and 
1.15 (IQR 0.65–2.21) and 7.40 (IQR 5.39–10.73) in the 
non-prednisone group, respectively.
In univariable analysis, a higher SES (based on the 
educational level of the mother) was associated with 
higher hair cortisol and cortisone concentrations, and a 
washing frequency ≥3 times with lower cortisol concen-
trations. Children born to mothers with a higher SES had 
a lower washing frequency of their hair. The association 
between SES and levels of cortisol and cortisone was not 
present in the multivariable model.
In the multivariable linear regression models, pred-
nisone exposure was not associated with hair cortisol 
and cortisone concentrations. The median of the mean 
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Figure 1 Flowchart of the study population and inclusion of study participants.
prednisone dose per day during pregnancy was 7.5 mg/
day (IQR 5.0–10.0). The mean prednisone dose and 
prednisone exposure in the first trimester were also not 
associated with these concentrations. In the multivari-
able models, only washing frequency was significantly 
associated with the levels of cortisone in hair. A washing 
frequency ≥3 times per week was associated with lower 
cortisone concentrations (p<0.05). Age, sex, season of 
hair collection and hair colour were not associated with 
hair cortisol and cortisone in the univariable and multi-
variable models.
Associations between antenatal prednisone exposure and 
anthropometric values
Antenatal prednisone exposure was not associated 
with the anthropometric measurements (BMI SDS, fat 
percentage SDS, waist circumference SDS, hip circumfer-
ence SDS, ratio waist-hip, ratio systolic blood pressure/
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Table 1 Descriptive statistics of study population
Prednisone (n=56)
Non-prednisone 
(n=61)
Reference population 
(n=150)
Age child, years, mean (SD) 10.0 (2.5) 9.6 (2.2) 9.8 (3.1)
Male 36 (64.3) 34 (55.7) 68 (45.3)*
Birth weight g, mean (SD) 3167.5 (691.9)* 3435.4 (584.2)* –
Birth weight SDS, mean (SD) −0.1 (1.0) −0.2 (1.2) –
Gestational age days, median (IQR) 273.0 (258.0–281)** 281.0 (274.0–287.0)** –
SES based on educational level of the mother
  Middle 15 (26.8) 23 (38.3) 21 (14.0)
  High 35 (62.5) 33 (55.0) 99 (66.0)
Black/brown hair colour 16 (28.6) 15 (24.6) 47 (31.3)**
Washing frequency (per week)≥3 25 (44.6) 25 (41.0) 52 (34.7)**
Season hair collection winter & fall 39 (69.6) 37 (60.7)
Maternal DAS28-CRP(3) in third trim, mean (SD) 3.7 (1.1)** 2.8 (0.9)**
Maternal age at delivery, years, mean (SD) 32.9 (3.8) 32.9 (3.9)
Maternal autoantibodies
  Present 33 (58.9) 35 (57.4)
  Absent 8 (14.3) 17 (27.9)
  Unknown 14 (25.0) 9 (14.8)
*P<0.05; **P<0.001, statistics were performed comparing the prednisone and non-prednisone group and the prednisone and non-prednisone 
group together vs the reference population.
DAS28-CRP(3), disease activity score in 28 joints using C reactive protein levels; SDS, SD scores; SES, socioeconomic status.
height, ratio diastolic blood pressure/height, and the 
ratio skinfolds trunk/peripheral), corrected for age, sex 
and SES (based on the educational level of the mother). 
The anthropometric values were also not associated with 
the hair cortisol and cortisone concentrations.
Associations with maternal RA disease activity
Maternal RA disease activity in the third trimester was 
not associated with hair cortisol and cortisone concen-
trations in the children. Maternal DAS28-CRP(3) in the 
third trimester was also not associated with the anthropo-
metric measurements.
Comparison with reference population
The median hair cortisol concentration in the refer-
ence population was 1.93 pg/mg (IQR 1.18–3.11). After 
log-transformation, cortisol was normally distributed.
Hair cortisol concentrations were not different 
between children born to mothers with RA and the refer-
ence population, corrected for the relevant variables 
mentioned previously, in a multivariate linear regres-
sion model. In this model, an older age of the child and 
higher weight SDS were significantly associated with 
higher cortisol levels (p<0.05).
disCussiOn
Prednisone is an anti-inflammatory drug that is 
prescribed to patients with an autoimmune disease, 
for example, RA, also during pregnancy. Research into 
the long-term side effects of prednisone use during 
pregnancy on the offspring has been limited. In this rela-
tively large and unique nationwide study, we followed the 
majority of the mothers and their children prospectively 
during and after pregnancy. The results of our study 
show that children with low-dose antenatal prednisone 
exposure do not have chronically elevated cortisol and 
cortisone concentrations in hair, compared with children 
without antenatal prednisone exposure. This is the first 
study to show these results prospectively from the ante-
natal period onwards in a (for this design) large cohort 
using scalp hair, reflecting chronic cortisol and cortisone 
concentrations. Adjustment for confounders allowed an 
independent analysis of the effects of antenatal pred-
nisone exposure in childhood.
Prednisone exposure was also not associated with 
anthropometric measurements like BMI SDS, fat 
percentage SDS, waist circumference SDS, hip circumfer-
ence SDS, ratio waist-hip and the ratio skinfolds trunk/
peripheral or with ratio systolic blood pressure/height 
and ratio diastolic blood pressure/height. Furthermore, 
maternal RA disease activity during pregnancy was not 
associated with cortisol and cortisone concentrations 
and anthropometric measurements. Children born to 
mothers with RA had a similar cortisol concentration 
compared with the reference population.
In general, antenatal exposure to glucocorticoids 
might result in chronically elevated cortisol and cortisone 
concentrations in the offspring.1–4 46 Previous studies, 
mostly animal but also in humans, demonstrated long-
term effects of maternal stress,8 maternal depression9 10 
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and maternal anxiety during pregnancy12–14 on cortisol 
concentrations or cortisol responses in offsprings. As 
mentioned before, adverse events during pregnancy have 
been shown to influence the development of the fetal 
HPA-axis. The systemic inflammation in patients with RA, 
and medication use during pregnancy are also consid-
ered as an adverse event during pregnancy. This is one of 
the few prospective studies in humans studying offspring 
antenatally exposed to synthetic glucocorticoids with the 
most reliable method to measure chronic cortisol and 
cortisone concentrations (in scalp hair).33 In our current 
study, we did not find any association between antenatal 
exposure to low-dose prednisone, maternal RA disease 
activity during pregnancy and long-term cortisol and 
cortisone concentrations or with an altered body compo-
sition or higher blood pressure in childhood.
In a previous study by de Steenwinkel et al,26 children 
born to mothers with RA with antenatal prednisone 
exposure had higher daytime cortisol levels (measured 
in saliva) compared with children without prednisone 
exposure. However, measuring cortisol in saliva is not 
a reliable method for long-term concentrations due to 
the circadian rhythm, pulsatile secretion, daily variation 
and reactivity to acute (transient) stress.21 29 30 Measuring 
cortisol in hair reliably reflects chronic concentrations. 
The elevated salivary cortisol levels in children with ante-
natal prednisone exposure born to mothers with RA 
from the study by de Steenwinkel et al26 could be a result 
of increased HPA-axis reactivity. However, for studying 
HPA-axis reactivity, cortisol concentrations should pref-
erably be measured before and after administrating 
a stressor. In another study by de Steenwinkel et al,52 
maternal RA disease activity during pregnancy and ante-
natal prednisone exposure had no influence on the body 
composition or on the risk for the metabolic syndrome 
of approximately 7-years-old offspring.52 In concordance 
with this study, we did not find either any associations 
between maternal RA disease activity during pregnancy, 
antenatal prednisone exposure and body composi-
tion in offspring aged approximately 10 years, which is 
reassuring. It is still possible that the consequences for 
these offsprings will emerge later in their life, therefore 
following these children until postpubertal age is inter-
esting for future research. The chronic use of prednisone 
and high RA disease activity are associated with reduced 
bone mineral density (BMD).53 54 In our study, we did not 
explore the effect of antenatal prednisone exposure on 
the BMD of the offspring. However, in a previous study by 
de Steenwinkel et al,55 they investigated the influence of 
medication use and disease activity of the mother during 
pregnancy on the offspring at the age of approximately 7 
years. In that study, a dual x-ray absorptiometry scan was 
performed in 108 children born to women with RA. They 
did not find any association between BMD and predni-
sone use or RA disease activity during pregnancy, even 
after correcting for all known associated variables, which 
is reassuring.
Currently, the treatment options for RA during preg-
nancy are prednisone, sulfasalazine, hydroxychloroquine 
and TNF-inhibitors.56 Most patients start with sulfasal-
azine or hydroxychloroquine, and when they do not 
respond to this therapy, prednisone or TNF-inhibitors 
are added. Compared with prednisone, TNF-inhibitors 
are expensive and worldwide not easily available for all 
patients with RA. Therefore, it is important that this study 
showed the long-term safety of maternal prednisone use 
during pregnancy.
Certain limitations should be taken into account when 
interpreting the results of this study. First, from the 252 
invited children (and their parents), 122 (48.4%) were 
willing to participate in this study. In total, 72 (28.6%) 
refused participation. Baseline characteristics were 
comparable between participants and non-participants. 
These findings decrease the likelihood that selection bias 
influenced the results of this study.
Second, in this study, the median of the mean pred-
nisone dose per day during pregnancy was 7.5 mg (IQR 
5.0–10.0). The use of prednisone concentrations above 
7.5 mg/day or even 10 mg/day might be more likely to 
influence the long-term cortisol and cortisone concen-
trations in the offspring. However, repeating the analyses 
in the children who were antenatally exposed to higher 
prednisone dosages (mean dose per day ≥10.0 mg), did 
not lead to different results. In addition, lower concentra-
tions of prednisone are often sufficient for the treatment 
of RA during pregnancy. Unfortunately, we did not have 
information on maternal weight during pregnancy for 
the majority of the participants. Maternal weight during 
the visit when the children’s hair was collected (child 
age approximately 10 years) was measured. However, 
since that would not be completely representative of the 
weight during pregnancy, prednisone dosages could not 
be corrected for maternal weight.
In conclusion, our study demonstrates that low-dose 
antenatal prednisone exposure and maternal RA disease 
activity during pregnancy are not associated with long-
term elevated cortisol and cortisone concentrations, 
an altered body composition or higher blood pressure 
in prepubertal childhood. Prednisone is an effective, 
low-priced antirheumatic drug that is considered safe to 
use during pregnancy. The findings of this study support 
the assumption that maternal prednisone use during 
pregnancy is safe for the offspring, at least until the age of 
approximately 10 years, which is reassuring for mothers 
who use prednisone and their physicians.
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